Published in J Pharmacokinet Pharmacodyn on July 23, 2010
A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer (2012) 1.38
Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response. Br J Clin Pharmacol (2015) 1.07
PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST. CPT Pharmacometrics Syst Pharmacol (2013) 0.93
Model-based treatment optimization of a novel VEGFR inhibitor. Br J Clin Pharmacol (2012) 0.86
Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas. Invest New Drugs (2014) 0.85
Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clin Cancer Res (2015) 0.85
Simultaneous Exposure-Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol. CPT Pharmacometrics Syst Pharmacol (2014) 0.83
Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis. Oncotarget (2016) 0.83
Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies. J Thyroid Res (2011) 0.81
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther (2014) 0.78
Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci (2015) 0.78
A Review of Modeling Approaches to Predict Drug Response in Clinical Oncology. Yonsei Med J (2017) 0.75
Successful recovery from a subclavicular ulcer caused by lenvatinib for thyroid cancer: a case report. World J Surg Oncol (2017) 0.75
Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment. Eur J Clin Pharmacol (2016) 0.75
Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications. Oncologist (2015) 0.75
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer. Onco Targets Ther (2016) 0.75
Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer. Mol Clin Oncol (2017) 0.75
K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis (2004) 6.66
PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed (2005) 6.36
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol (2005) 5.27
Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther (1979) 5.13
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol (2008) 4.27
Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm (1993) 3.96
Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol (2006) 3.59
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis (2007) 3.47
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer (2007) 2.68
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol (2008) 2.63
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet (2008) 2.36
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer (2006) 2.33
Dose selection in phase I studies: why we should always go for the top. J Clin Oncol (2008) 2.08
Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res (2008) 2.05
E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer (2008) 2.04
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol (2009) 1.82
Hypertension as a predictive factor of Sunitinib activity. Ann Oncol (2007) 1.78
Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res (2008) 1.60
Approaches to handling pharmacodynamic baseline responses. J Pharmacokinet Pharmacodyn (2008) 1.59
Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med (2001) 1.55
Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res (2011) 1.41
Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med (2008) 1.36
Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant (1995) 1.15
Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements. Clin Pharmacol Ther (1998) 0.98
Prevalence, concentration, and prognostic importance of proteinuria in patients with malignancies. Br Med J (Clin Res Ed) (1988) 0.93
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet (2011) 4.73
Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J (2011) 4.60
Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis (2013) 4.03
Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J (2009) 3.99
Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn (2007) 3.00
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst (2002) 2.84
The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A (2002) 2.79
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther (2002) 2.60
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res (2011) 2.52
Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res (2007) 2.51
Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn (2008) 2.50
Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol (2002) 2.44
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol (2002) 2.43
Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed (2010) 2.34
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J Clin Oncol (2011) 2.24
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother (2012) 2.14
Handling data below the limit of quantification in mixed effect models. AAPS J (2009) 2.11
Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet (2010) 2.08
Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother (2004) 2.08
Photodynamic therapy in oncology. Oncologist (2006) 2.04
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol (2010) 2.03
A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res (2009) 2.01
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol (2011) 1.95
Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother (2008) 1.95
Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism. Arch Intern Med (2004) 1.92
Development of farnesyl transferase inhibitors: a review. Oncologist (2005) 1.90
Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS (2002) 1.84
Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet (2005) 1.84
Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet (2004) 1.82
P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res (2007) 1.74
Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci (2002) 1.72
Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study. Drugs Aging (2010) 1.69
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res (2011) 1.66
Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clin Cancer Res (2006) 1.65
Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol (2002) 1.64
Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chem (2003) 1.63
Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell (2011) 1.62
Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncol (2009) 1.61
Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol (2006) 1.60
Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci (2005) 1.59
Approaches to handling pharmacodynamic baseline responses. J Pharmacokinet Pharmacodyn (2008) 1.59
Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther (2005) 1.58
Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother (2008) 1.58
Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet (2005) 1.57
Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children. Clin Cancer Res (2011) 1.57
Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol (2011) 1.55
Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. AIDS (2003) 1.54
On the rate and extent of drug delivery to the brain. Pharm Res (2007) 1.53
Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol (2010) 1.53
A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin Cancer Res (2004) 1.51
The effects of fall-risk-increasing drugs on postural control: a literature review. Drugs Aging (2013) 1.50
Drug interactions in oncology. Lancet Oncol (2004) 1.49
An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol (2003) 1.49
Cardiopulmonary imaging, functional and laboratory studies in sickle cell disease associated pulmonary hypertension. Am J Hematol (2008) 1.49
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst (2006) 1.48
Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin. Br J Clin Pharmacol (2012) 1.48
Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther (2005) 1.45
Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet (2003) 1.43
Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist (2006) 1.43
Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin Cancer Res (2009) 1.42
Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res (2003) 1.42
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest (2007) 1.41
Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients. Eur Urol (2012) 1.41
Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer (2010) 1.41
Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer (2011) 1.40
Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity. Mol Diagn Ther (2007) 1.39
Incidence and risk factors for nevirapine-associated rash. Eur J Clin Pharmacol (2003) 1.39